Publications

Add filters (0)

351 results

Endotrophin Measured by PRO-C6 as a Prognostic Biomarker for Liver-Related Events in Patients With Advanced Chronic Liver Disease.

September 1, 2026

Liver Int

Abstract BACKGROUND & AIMS Prognostic non-invasive tests for liver-related events in compensated cirrhosis are needed. Endotrophin, a fragment of type VI alpha 3 collagen involved in fibrosis and inflammation, has been associated with adverse outcomes in several chronic diseases. This study examined the association between baseline endotrophin levels, measured by nordicPRO-C6 (PRO-C6), and liver-related events […]

Read publication

Combination therapy of RAS inhibition and glucagon-like peptide-1 receptor agonist improves a marker of kidney fibrosis in people with type 2 diabetes.

September 1, 2026

Am J Physiol Cell Physiol

Abstract In type 2 diabetes (T2D), kidney fibrosis drives the progression of chronic kidney disease (CKD) and kidney failure. Lower urinary levels of collagen type III degradation (C3M), a biomarker of extracellular matrix (ECM) turnover, have been associated with CKD progression. We investigated the effect of combination therapy with renin-angiotensin system inhibition (RASi) and glucagon-like […]

Read publication

Prospective validation of imaging and serum diagnostic biomarkers of steatohepatitis and fibrosis in MASLD: the LITMUS Imaging Study.

August 1, 2026

Nat Med

Abstract There is a need for robust evaluations of noninvasive biomarkers for metabolic dysfunction-associated steatotic liver disease. This prospective multicenter study assessed the diagnostic accuracy of imaging (including liver stiffness measurement (LSM) using magnetic resonance elastography (MRE) and FibroScan (vibration-controlled transient elastography (VCTE)), serum biomarkers (including NIS2+) and composite scores (including Agile 3+ and Agile […]

Read publication

Skeletal muscle proteomics links mitochondrial abundance with peak fat oxidation in physically active young males.

July 1, 2026

J Physiol

Abstract The interindividual variability in peak fat oxidation (PFO) and the intensity at which this occurs (Fat) has been attributed to physiological factors, diet and physical activity; however, few studies have examined the contribution of skeletal muscle characteristics. The present study examined the relationship between PFO, Fat and the skeletal muscle proteome in young, physically […]

Read publication

Two-step care pathways for advanced MASLD in primary and hospital care: A multicenter study.

July 1, 2026

Hepatol Commun

Abstract BACKGROUND Early diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) fibrosis may prevent liver-related morbidity and mortality. We investigated the effectiveness of multiple 2-step approaches for detecting at-risk advanced MASLD fibrosis, defined as a hierarchical clinical score comprising liver histology and VCTE depending on availability, in primary and hospital outpatient care. METHODS Patients at […]

Read publication

Extracellular matrix biomarkers of T-cell infiltration and tumor fibrosis predict response to nivolumab ± ipilimumab with SBRT in biliary tract cancer: insights from the CheckPAC trial.

June 11, 2026

BMC Med

Abstract BACKGROUND Biliary tract cancer (BTC) is an uncommon malignancy with limited treatment options and poor prognosis. BTC is typically characterized by a desmoplastic, collagen-rich extracellular matrix (ECM), which has been linked to immune exclusion and therapy resistance. Although immune checkpoint inhibitors (ICI) combined with gemcitabine/cisplatin have become first-line treatment for advanced BTC, durable responses […]

Read publication

Pilot trials of oral betaine in participants with metabolic dysfunction-associated steatotic liver disease and elevated alanine aminotransferase.

June 1, 2026

Hepatology

Abstract BACKGROUND AND AIMS Betaine, 20 g/day for 12 months, reduced liver injury in several trials in non-alcoholic steatohepatitis (NASH). Our aim was to determine the safety and efficacy of lower doses of betaine in clinically diagnosed metabolic dysfunction-associated steatotic liver disease (MASLD) and an elevated ALT. APPROACH AND RESULTS We performed 3 pilot trials in […]

Read publication

The role of type I collagen fragment C1M in knee osteoarthritis. A longitudinal biomarker study using data from the OA-FNIH consortium.

June 1, 2026

Osteoarthritis Cartilage

Abstract OBJECTIVE To evaluate the association of neoepitopes from type I and II collagen with knee osteoarthritis (OA) progression phenotypes using data from the OA-FNIH biomarker consortium, with comparison to associations of the other biomarkers assessed in this sample during the consortium’s phase 1 analysis. DESIGN Serum (s) and urinary (u) neoepitopes of type I […]

Read publication

Collagen protein supplementation does not modulate biomarkers of bone metabolism following total hip arthroplasty: a randomized, double-blind, placebo-controlled trial.

June 1, 2026

Clin Nutr ESPEN

Abstract BACKGROUND & AIMS Healing after total hip arthroplasty (THA) involves remodelling of collagenous tissues, such as bone. While collagen protein supplementation has been suggested to modulate bone metabolism, the effects following THA are yet to be investigated. Therefore, we aimed to characterize changes in biomarkers of bone metabolism following THA and to assess the […]

Read publication

Accelerated basement membrane remodeling and serum matrix fragments as biomarkers of fibrosis in Alport syndrome.

May 26, 2026

Cell Rep

Abstract Chronic kidney disease (CKD) is characterized by fibrosis. Alport syndrome, a common monogenic form of CKD caused by collagen type IV variants, leads to basement membrane defects and progressive fibrosis. Understanding extracellular matrix dynamics is crucial for identifying disease-specific biomarkers and optimizing therapeutic timing. We applied a discovery approach combining stable C-lysine metabolic labeling […]

Read publication